BioKangtai: Application for marketing authorization of trivalent influenza virus split vaccine accepted
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, BioKangtai announced that the company's application for marketing authorization of the influenza virus split vaccine has recently received the "Acceptance Notice" issued by the National Medical Products Administration. This marketing authorization application for the influenza virus split vaccine is applicable to individuals aged 3 years and older and can stimulate the body to produce immunity against the influenza virus, used for the prevention of influenza caused by vaccine-related strains of the influenza virus
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments